EUVIMEDEUVIMED entdecken
Crossref

Number of Lymph Nodes Examined as a Prognosis Factor in Patients With Stage II or III Colon Cancer

Hyunwook Kim, Lingjie Shen, Jeongseok Jeon, Yoon Dae Han, Dai Hoon Han, Minsun Jung, Seo Jeong Shin, Seng Chan You, Nam Kyu Kim, Byung Soh Min, Hyuk Hur, Joong Bae Ahn und 5 weitere

Clinical Colorectal Cancer · 2025

DOI: 10.1016/j.clcc.2025.02.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Colorectal Cancer, 2025. Verfasst von Hyunwook Kim und 16 weiteren Autor:innen. Beteiligte Einrichtung: Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Colonic Neoplasms, Lymph Nodes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Korea Health Industry Development Institute, Ministry of Health and Welfare, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Lymph node (LN) examination is important for staging colorectal cancer. Examining < 12 LN has been associated with a poor prognosis. However, surgical and pathological advances have led to increase examined LN, necessitating the reassessment of the best cutoff for prognosis. PATIENTS AND METHODS: We reviewed patients with stage II-III colon cancer from the Yonsei Cancer Center Registry (YCC) database and the Netherlands Cancer Registry (NCR). The optimal LN cutoff was determined by comparison with hazard ratio (HR) in 12 LN. We compared higher vs. lower LN cutoff effects on a 6-year overall survival (OS). RESULTS: From 2005 to 2015, the proportion with < 12 LN decreased significantly (P < .001). There was no significant association between 6-year OS and LN yield in all stages II-III patients (HR = 1.21, P = .116), stage II (HR = 1.39, P = .068), and stage III (HR = 1.18, P = .297) colon cancer based on the standard 12 LN examined, whereas the 20 LN cutoff examined was associated with a significant increase in 6-year OS in all patients (HR = 1.51, P < .001). Multivariate regression revealed a significant decrease in 6-year OS in stage II (HR = 1.39, P = .026) and stage III (HR = 1.47, P < .001) with < 20 LN yield. In the NCR, < 20 LN was associated with poorer 6-year OS in stage II-III patients (HR = 1.25, P < .001), stage II (HR = 1.43, P < .001), and stage III (HR = 1.13, P = .007). CONCLUSION: Over the past decade, inadequate LN examinations have significantly decreased. Compared to < 12 LN, < 20 LN examined is more associated with a worse prognosis in patients who underwent surgery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colonic NeoplasmsLymph NodesHumansMaleFemaleNeoplasm StagingPrognosisAgedMiddle AgedLymphatic MetastasisNetherlandsLymph Node ExcisionRetrospective StudiesRegistriesAged, 80 and overAdultSurvival RateFollow-Up Studies

Stichwörter der Autor:innen

Colon CancerCutoffHigh riskLymph node yieldN2 diseaseOverall survival

Autor:innen und Institutionen

  • Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
  • Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands.
  • Yonsei University College of Medicine, Seoul, South Korea.
  • Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea.
  • Department of Pathology, Yonsei University College of Medicine, Seoul, South Korea.
  • Institute for Innovation in Digital Healthcare, Yonsei University Health System, Seoul, South Korea.

Förderung

  • Korea Health Industry Development Institute
  • Ministry of Health and Welfare
  • National Research Foundation of Korea
  • Korea Ministry of Science and ICT

Zitieren

APA

Kim, H., Shen, L., Jeon, J., Han, Y. D., Han, D. H., Jung, M., Shin, S. J., You, S. C., Kim, N. K., Min, B. S., Hur, H., Ahn, J. B., Shin, S. J., van Gestel, A. J., van Erning, F. N., Geleijnse, G., & Kim, H. S. (2025). Number of Lymph Nodes Examined as a Prognosis Factor in Patients With Stage II or III Colon Cancer. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2025.02.004

Vancouver

Kim H, Shen L, Jeon J, Han YD, Han DH, Jung M, et al. Number of Lymph Nodes Examined as a Prognosis Factor in Patients With Stage II or III Colon Cancer. Clinical Colorectal Cancer. 2025. doi:10.1016/j.clcc.2025.02.004

BibTeX
@article{Kim2025,
  author = {Kim, Hyunwook and Shen, Lingjie and Jeon, Jeongseok and Han, Yoon Dae and Han, Dai Hoon and Jung, Minsun and Shin, Seo Jeong and You, Seng Chan and Kim, Nam Kyu and Min, Byung Soh and Hur, Hyuk and Ahn, Joong Bae and Shin, Sang Joon and van Gestel, Anna Jacoba and van Erning, Felice N and Geleijnse, Gijs and Kim, Han Sang},
  title = {Number of Lymph Nodes Examined as a Prognosis Factor in Patients With Stage II or III Colon Cancer},
  journal = {Clinical Colorectal Cancer},
  year = {2025},
  doi = {10.1016/j.clcc.2025.02.004}
}
Kostenlos starten →